(AMRN) Amarin Corporation plc Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMRN) Amarin Corporation plc Complete Analysis Pack
A Must-Have Tool for Decision-Makers
This Amarin Corporation plc Porter's Five Forces Analysis helps you quickly understand the competitive pressures shaping the company’s market, including rivalry, buyer power, supplier power, substitutes, and new entrants. This page already shows a real preview of the actual report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized API sourcing
Amarin Corporation plc depends on qualified omega-3 active pharmaceutical ingredient suppliers, so the buyer base is narrow and supplier leverage is real. In pharma, only vendors that meet tight purity and regulatory standards can supply VASCEPA inputs, which limits substitutions and can lift pricing or tighten delivery terms. That concentration can squeeze margins if sourcing is interrupted or costs rise.
Manufacturing compliance burden
GMP-grade suppliers are scarce, so Amarin Corporation plc cannot switch vendors quickly. Every partner must pass inspections, keep batch consistency, and meet FDA and other global quality rules, which raises switching costs and strengthens supplier leverage. In a market where regulatory failure can halt production, compliant manufacturers hold more bargaining power than Amarin.
Packaging and logistics constraints
Amarin Corporation plc depends on specialized packaging, temperature-controlled logistics, and pharma distribution to keep Vascepa safe and traceable across markets. With only a small pool of vendors able to meet GMP and chain-of-custody needs, those suppliers can push pricing and service terms higher. That makes supplier power modestly elevated, especially for regulated international shipments.
Limited formulation know-how
Amarin Corporation plc’s deal with Mochida Pharmaceutical shows how Vascepa’s EPA know-how sits with a small set of firms, not a broad supplier base. That makes supplier expertise a bottleneck, so Amarin has less room to switch vendors or push terms. The result is higher switching costs and weaker bargaining power.
- Know-how is concentrated.
- Switching costs rise.
- Flexibility falls.
Moderate leverage overall
Amarin Corporation plc has moderate supplier leverage because it is not a large diversified buyer, so it lacks the scale discounts of big pharma. It can still multi-source some non-core inputs and outsource selected work, which limits supplier control. That keeps bargaining power from turning high. Overall, supplier power is moderate.
- Smaller buyer scale weakens leverage.
- Non-core inputs can be multi-sourced.
- Selective outsourcing caps supplier power.
- Net effect: moderate supplier leverage.
Amarin’s Supplier Power Is Moderate-High
Amarin Corporation plc’s supplier power is moderate to high because VASCEPA depends on a small pool of GMP-qualified EPA and packaging vendors, with key know-how tied to one core partner. That raises switching costs and gives suppliers room on price and lead times. FDA-grade compliance keeps alternatives limited.
| Metric | Impact |
|---|---|
| Core EPA know-how partners | 1 key source |
| Supplier switch time | High |
| Regulatory filter | Strict GMP/FDA |
| Bargaining power | Moderate-high |
What is included in the product
Detailed Word Document
Assesses Amarin Corporation plc’s competitive pressures, bargaining power, and threat of substitutes to gauge profitability and market risk.
Customizable Excel Spreadsheet
A quick Porter's Five Forces snapshot for Amarin Corporation plc—cutting through competitive complexity to support faster, clearer strategy decisions.
Reference Sources
Provides a concise, traceable source trail for Amarin Corporation plc, boosting credibility and speeding investment decisions.
Customers Bargaining Power
Concentrated wholesale channels
Amarin sells mainly through a few large wholesalers and specialty pharmacy providers, so buyers are concentrated. That concentration lets them push for rebates, fees, and service terms, and it can shape access to distribution and inventory. In practice, that gives intermediaries meaningful leverage over Amarin’s net price and sell-through.
Payer and formulary pressure
Insurers and pharmacy benefit managers can block or steer demand with formulary exclusion, prior authorization, and rebate demands, so physician interest does not always become Amarin Corporation plc sales. This matters more in prescription drugs because payers control access and net price, not just patients and doctors. For Amarin Corporation plc, that gives buyers strong power and makes price realization harder even when clinical demand exists.
Price sensitivity in lipid therapy
Patients and payers compare VASCEPA with low-cost omega-3 and generic options, so price pressure stays high in lipid therapy. In Amarin Corporation plc's latest reported year, net revenue was about $200 million, and that scale still leaves room for buyers to demand lower net prices if clinical benefit is not fully reimbursed. In markets with broad statin and lipid-lowering access, customer bargaining power remains strong.
Physician-prescriber influence
Amarin Corporation plc’s physician-prescriber influence is limited because doctors can choose Vascepa, but they cannot override formulary and reimbursement rules. With only 1 core prescription brand, a payer block can stop uptake even when clinical data are strong, so buyers and payers still hold more power than prescribers alone.
1 brand means access risk stays concentrated.
Payers can cap volume through coverage rules.
Amarin must sell both clinical and reimbursement value.
Limited direct end-user leverage
Individual patients have little direct negotiating power with Amarin Corporation plc, but they can still cut demand fast if copays are too high or benefit feels weak. The 2025 Medicare Part D out-of-pocket cap is $2,000, yet commercial coverage and step edits still drive switch risk for Vascepa. End-user power is indirect, but it can hit refill volume quickly.
That matters because Amarin Corporation plc depends on continued therapy, not one-time sales. If access barriers rise, adherence falls, and even small drops in persistency can move revenue. One line: patients do not bargain much, but they can walk away.
- Low direct patient leverage
- Copays can cut refill volume
- Coverage shapes therapy stay rates
- Access shocks pass through fast
High Buyer Power Keeps Amarin’s Sales Under Pressure
Customer bargaining power is high for Amarin Corporation plc because a few wholesalers, PBMs, and insurers control access, rebates, and net price. VASCEPA also faces low-cost omega-3 and generic pressure, so coverage rules can cap volume fast. In 2025, net revenue was about $200 million, showing how buyer leverage still shapes sales.
| Factor | 2025 data | Effect |
|---|---|---|
| Net revenue | About $200 million | Buyer leverage remains strong |
| Core brand | 1 | Access risk is concentrated |
Full Version Awaits
Amarin Corporation plc Porter's Five Forces Analysis
This preview shows the exact Amarin Corporation plc Porter’s Five Forces Analysis you’ll receive after purchase—no edits, no placeholders, and no surprises. It’s the same professionally written, ready-to-use document displayed here in full. Once you buy, you’ll get immediate access to this exact file.
Rivalry Among Competitors
Direct omega-3 competition
VASCEPA faces direct pressure from other triglyceride-focused and omega-3 therapies, including products aimed at the same patients with triglycerides 150 mg/dL or higher and severe hypertriglyceridemia at 500 mg/dL or higher. The market is crowded, so clinical claims, payer coverage, and price drive share more than brand alone. With 4 g/day dosing and overlapping cardiovascular use, rivals can target the same populations and keep rivalry high.
Generic erosion risk
Generic entry can hit Amarin Corporation plc fast: in pharma, the first low-cost copy often cuts branded prices by 80% to 90% and can drain most sales within 12 months. That matters because Amarin already faces icosapent ethyl copies, so rivalry rises even if branded rivals stay few. In FY2025, that pressure can keep margins thin and make share defense harder.
Evidence-based differentiation
Cardiovascular drugs compete on outcomes data, safety, and guideline support. VASCEPA’s edge rests on REDUCE-IT, which showed a 25% relative cut in major adverse cardiovascular events, but Amarin still has to defend that profile against rival therapies and tough formulary review. If a competitor offers similar efficacy or wider labels, payers can switch share fast, so rivalry stays high in both sales and medical affairs.
Geographic competition
Amarin competes in at least five markets: the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Rivalry changes by country because reimbursement, prescribing habits, and generic penetration differ, so Amarin faces several competitive arenas at once. Cross-border pricing, access, and launch rules add friction and keep rivalry high.
- Five-country footprint raises rivalry.
- Local payers shape access.
- Generic pressure varies by market.
- Cross-border complexity weakens scale.
Innovation and lifecycle pressure
Pharma rivals keep pressure high by adding new indications, better formulations, and stronger clinical data. Amarin still depends on VASCEPA/VAZKEPA as its only commercial asset, so any delay in new data or partnerships leaves it vulnerable to faster-moving peers. That makes rivalry moderate to high.
- One asset means limited pipeline cushion
- New evidence can shift prescribing fast
- Collaboration helps, but cannot replace pipeline momentum
Amarin Faces Intense Rivalry as VASCEPA Battles Price and Access
Competitive rivalry is high for Amarin Corporation plc because VASCEPA competes on outcomes data, price, and payer access, not brand alone. In FY2025, icosapent ethyl copy pressure kept pricing under strain, and the company still relied on one commercial asset.
REDUCE-IT showed a 25% relative cut in major adverse cardiovascular events, but rivals can still win share through formulary access or cheaper copies. Amarin’s five-country footprint also adds local pricing and reimbursement battles.
| Key rivalry factor | Latest data |
|---|---|
| Core asset | 1 product |
| Clinical edge | 25% MACE reduction |
| Market scope | 5 countries |
| Generic pressure | High in FY2025 |
Substitutes Threaten
Lifestyle and diet management
VASCEPA is an adjunct to diet, so lifestyle changes are a direct substitute and a complement. A 5% to 10% weight loss can cut triglycerides by about 20%, and regular exercise plus lower sugar and alcohol intake can further reduce levels. In milder cases, these measures can delay or avoid prescription use, so the substitute threat is meaningful.
Alternative lipid-lowering drugs
Statins remain the first-line lipid-lowering option, and generic fibrates and other cardiovascular drugs can meet similar risk-reduction goals. In Amarin Corporation plc's 2025 results, revenue was $155.4 million, showing how price-sensitive demand stays in this market. If a physician sees better fit on risk or reimbursement, demand can shift away from Amarin Corporation plc, so substitution risk is high.
OTC omega-3 products
OTC fish oil and omega-3 supplements are easy to buy and often cost far less than prescription VASCEPA, which is taken at 4 g/day. Because of that, some patients see them as a cheaper enough substitute, even though they are not clinically equivalent for FDA-approved uses. That price gap can pressure Amarin Corporation plc’s pricing power, especially in price-sensitive markets.
Emerging cardiometabolic therapies
Emerging cardiometabolic drugs are already changing care: Novo Nordisk reported 2024 sales of DKK 290.4bn, with GLP-1 use reshaping obesity, diabetes, and cardiovascular-risk treatment. As prescribers choose therapies that can lower weight and A1C at the same time, triglyceride-focused drugs like Amarin's face indirect substitution pressure. Amarin must compete in a broader risk-reduction market, not just the lipid niche.
- GLP-1s widen treatment choices.
- Weight loss can displace TG drugs.
- CV-risk focus expands substitution risk.
Moderate-high substitution pressure
Amarin Corporation plc faces moderate-high substitution pressure because VASCEPA (icosapent ethyl) is clinically useful, but it is not the only option for lipid management. Payers and physicians can still choose statins, generic omega-3 products, or other cardiovascular risk-reduction paths, so Amarin’s pricing power stays limited.
This matters because VASCEPA’s role is specific, not exclusive, and that makes switching easier when cost or coverage changes. In a market where generic statins already dominate, substitutes can cap growth and keep reimbursement pressure high.
- Multiple treatment paths reduce stickiness.
- Generics cap pricing and expansion.
- Payers can push cheaper alternatives.
- Overall pressure: moderate to high.
Amarin Faces Intense Substitute Pressure in 2025
Threat of substitutes for Amarin Corporation plc is high: VASCEPA competes with statins, fibrates, OTC omega-3s, and broader cardiometabolic drugs. In 2025, Amarin Corporation plc revenue was $155.4 million, and that size shows how quickly patients and payers can switch to cheaper or broader options.
| Substitute | Impact |
|---|---|
| Statins | First-line, low-cost |
| OTC omega-3 | Cheaper, easy access |
| GLP-1 drugs | Broader risk reduction |
Entrants Threaten
Heavy regulatory barriers
For Amarin Corporation plc, heavy regulatory barriers keep new entrants out: the U.S. FDA approved just 50 novel drugs in 2024, showing how selective the gate is. New pharma players must fund large clinical trials, GMP quality systems, and multi-country filings before launch. Those long timelines and high costs deter most rivals and keep entry barriers high.
High capital and development costs
High capital needs keep new entrants out of Amarin Corporation plc’s space. Developing a cardiovascular drug can cost about $2.6 billion and take 10-15 years, with Phase 3 trials alone often running tens of millions of dollars. After approval, payer access, sales force buildout, and physician trust add more cash burn, so smaller rivals rarely reach scale.
Patent and exclusivity hurdles
Amarin Corporation plc still benefits from layers of patent and regulatory exclusivity around its product and key formulations, but those protections keep shifting as litigation plays out. New entrants must clear patents, generic challenges, and launch risk, which can add millions in legal and filing costs and slow market access. That uncertainty makes fast entry less likely and raises the bar for rivals.
Reimbursement and distribution barriers
Reimbursement and distribution are hard gates for Amarin Corporation plc new entrants. Payers, wholesalers, and specialty pharmacies already back branded cardiovascular drugs with proven outcomes, so a newcomer must spend heavily on evidence, contracts, and access.
That makes entry slower and pricier than in many sectors, because formulary wins and channel access are built over years, not months.
- Formulary access is a high hurdle.
- Channel ties favor incumbents.
- New entrants need heavy spend.
Low threat overall but not zero
Threat of new entrants for Amarin Corporation plc is low to moderate. VASCEPA's entry risk is mainly from specialized generic or reformulation players, not new startups, because FDA rules, clinical proof, and payer access are hard gates. The biggest openings come when patents weaken, so broad entry stays rare but targeted challengers can still appear.
- High regulation blocks easy entry
- Patents weaken, then rivals test access
- Generic or reformulated VASCEPA is the main risk
Amarin’s New Entrant Risk Stays Low
Amarin Corporation plc faces a low threat of new entrants because FDA, trial, and reimbursement barriers are steep. In 2024, the FDA approved 50 novel drugs, and cardiovascular drug development can cost about $2.6 billion over 10-15 years. Entry is most likely from generic or reformulation players once patent shields weaken.
| Barrier | Impact |
|---|---|
| FDA access | Low |
| R&D cost | $2.6B |
| Time to launch | 10-15 years |
| Entry risk | Generic challengers |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.